Progesterone and Breast Tissue: The Bioidentical Distinction

What WHI found

The Women's Health Initiative trial (2002) showed increased breast cancer in the HRT arm vs. placebo. This was widely reported and caused massive HRT discontinuation. The HRT used was conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA), a synthetic progestin.

Progestin vs. progesterone

Important distinction:

• Progesterone, the natural hormone produced by the corpus luteum and (during pregnancy) placenta
• Progestin, synthetic compound that activates progesterone receptors; designed for contraceptive and HRT use

Progestins (MPA, norethindrone, levonorgestrel) are chemically distinct from progesterone. They activate progesterone receptors but also have other receptor activities (androgenic, glucocorticoid, anti-mineralocorticoid) that vary by molecule.

Bioidentical progesterone data

Subsequent studies of HRT using bioidentical progesterone:

• The French E3N cohort showed no significant breast cancer increase with bioidentical progesterone
• Other large observational studies similarly suggest different risk profile from progestins
• Mechanism studies show bioidentical progesterone has different effects on breast tissue than MPA
• Animal studies confirm progestin breast effects differ from progesterone

Mechanism difference

Why the difference?

• MPA has substantial androgenic and glucocorticoid activity in addition to progesterone receptor activation
• Bioidentical progesterone is more selective for progesterone receptors
• Breast tissue responds differently to the different signaling profiles
• Bioidentical progesterone may even have anti-proliferative effects in some contexts

Current practice

For modern HRT in 2026:

• Bioidentical micronized progesterone preferred when progestogen needed (with estrogen, for endometrial protection)
• Synthetic progestins less commonly used for HRT (still used in contraception)
• The "HRT causes breast cancer" framing applies more to progestins than to bioidentical progesterone
• For women without uterus, estrogen-only HRT is appropriate (no progestogen needed for endometrial protection)

Bottom line

The WHI breast cancer signal came from synthetic progestin (MPA), not bioidentical progesterone. Subsequent data on bioidentical micronized progesterone shows different and more favorable breast risk profile. Modern HRT typically uses bioidentical progesterone. The distinction is important for patients weighing HRT decisions.